How big tech is recalibrating around the DeepSeek threat
Silicon Valley owes its longevity to its ability to pivot and China’s new AI start-up could set it moving in a new direction.
Victoria Business
Faltering coal and record gas exports drive energy price rises
The challenges faced by the electricity grid have been thrown into sharp relief as record solar output fails to offset coal outages and a lack of interconnection, driving spot prices higher.
Return of Aussie wine to China fires up exports in sluggish market
Australian winemakers are sitting on a glut of mainly red but the reopening of the post-tariff Chinese market has helped ease the pressure by lifting exports 34 per cent in 2024.
Sigma shareholders wave through $34bn Chemist Warehouse deal
There’s no reason Chemist Warehouse’s strong growth won’t continue, the Sigma Healthcare chair says, as the $34bn merger of the two companies passes a crucial vote.
More Stories
Cosmetics operator delays bourse listing
Cosmetic injectables clinic operator Stormeur has pushed back its ASX listing as it looks to raise more capital.
How AUKUS is creating big waves on the ground
There are billions earmarked to be spent, and this Perth-based engineer is among those on the front lines of a defence revolution.
Burning cash: Star’s future can be counted in months
New boss Steve McCann has his work cut out to come up with a deal to save the casino. But he is fast running out of options.
Are we there yet? Howard Marks revisits bubble.com warning
A quarter of a century after predicting the dot.com crash, influential US billionaire investor Howard Marks sees some worrying signs returning to shares.
Behind Nvidia’s plan to control the new industrial revolution
Jensen Huang is betting Nvidia’s future is far bigger than the chips powering today’s AI boom.
Nine faces its make or break-up moment
The under-pressure broadcaster was prepared to bet big on television and lost. Now it has a fight on its hands to prove it should stay together.
US regulatory approval heralds new class of drugs, says Mesoblast
Mesoblast winning approval for its Ryoncil drug in the US opens the path for nothing less than the arrival of a new class of drugs, managing director Silviu Itescu says.
How Trump’s tariffs will disrupt stockmarkets
Hefty new taxes on US imports from various countries was a Trump election platform, but what does it mean for your shares?
Battle of the asset classes: the investments likely to grow in 2025
Shares surged higher in 2024 and their returns will be tough to repeat in 2025, but other investment opportunities appear attractive.
Melbourne start-up signs blockbuster pharmacy deal
A tech firm that streamlines how chemists find pharmacists for locum shifts has signed up Australia’s biggest player, as it expands to the US and into other fields.
Original URL: https://www.adelaidenow.com.au/business/victoria-business/page/5